OKYO Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd., a foreign private issuer filing under Form 20-F, furnished this Form 6-K on March 24, 2023. The filing reports an insider-related purchase of the company’s American Depositary Shares (ADSs) and includes the related announcement as Exhibit 99.1.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial metrics. No financial statements or financial guidance are included.
Material Changes and Insider Transaction
- Panetta Partners Limited purchased 10,000 OKYO ADSs on Nasdaq at $1.40 per ADS.
- Gabriele Cerrone, the company’s Executive Chairman, has a beneficial interest in Panetta Partners Limited.
- The aggregate reported purchase value was approximately $14,000, before any transaction costs.
- The filing does not provide a prior comparable-period transaction or operating-performance comparison.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management discussion, contingencies, or material risk disclosures are provided in the filing. The reported transaction is an insider-related securities purchase. Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 liability or incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the 10,000-ADS purchase, $1.40 purchase price, and approximately $14,000 aggregate value.
- Confirm Panetta Partners Limited’s beneficial-interest relationship with Executive Chairman Gabriele Cerrone.
- Review Exhibit 99.1 for any additional transaction details or disclosures.
- Consult the company’s periodic reports for current financial condition, liquidity, operating results, and risk factors.